Life sciences capabilities
The business of vital innovation
How we can help you
Despite soaring global demand for healthcare, the challenge of profitably developing treatments has never been greater or more ethically complex. Can pharma giants strike the right balance?
Recent insights
21 September 2026
Cross Examining Cyber: Conversations with cyber leaders
21 September 2026
Are you cyber ready? Australian legal leaders' views on the cyber risk landscape
1 September 2026
The Unified patent court and unitary patent – An introduction
1 September 2026
Pharma M&A is back - H1 2026 Update
11 August 2026
The new cost of capital for early investment in Indonesia: Governance, diligence and recalibration
11 August 2026
Indonesian Hospitals: Key Regulatory Changes to Hospital Classification, Investment and Operations
30 Juli 2026
Three years of the UPC – A court coming of age
30 Juli 2026
The EU Commission's new draft merger guidelines - key takeaways for pharma companies
30 Juli 2026
2026 sees China's biotech scene continuing its ascent – but could US developments mean clouds on the horizon?
30 Juli 2026
The EU Pharma Package is finally here – here's the settled position on key areas
20 April 2026
FDA pushes for broader powers to curb misleading direct to consumer drug advertising
1 April 2026
UPC Structure – local, regional and central divisions and Court of Appeal, Judges & Languages
Key contacts
Alan Montgomery
Partner, Head of Life Sciences Sector, Chair of India Group, London
Chris Parker KC
Partner, Head of Life Sciences Sector, London
Natalie Bryce
Partner, Head of Healthcare Sector, Brisbane